Karuna Therapeutics (KRTX) Stock Forecast, Price & News

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRTX shares.
View KRTX analyst ratings or view top-rated stocks.

15 Wall Street analysts have issued 1-year target prices for Karuna Therapeutics' stock. Their KRTX share price forecasts range from $209.00 to $330.00. On average, they predict the company's stock price to reach $275.44 in the next year. This suggests a possible upside of 16.6% from the stock's current price.
View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts.

Karuna Therapeutics' stock was trading at $196.50 on January 1st, 2023. Since then, KRTX stock has increased by 20.3% and is now trading at $236.30.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our KRTX earnings forecast.

Karuna Therapeutics, Inc. (NASDAQ:KRTX) posted its earnings results on Thursday, May, 4th. The company reported ($2.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.86) by $0.06. The business earned $0.65 million during the quarter. Karuna Therapeutics had a negative trailing twelve-month return on equity of 30.04% and a negative net margin of 2,795.96%. During the same period in the previous year, the company posted ($1.95) earnings per share.

ETFs with the largest weight of Karuna Therapeutics (NASDAQ:KRTX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Nuveen ESG Small-Cap ETF (NUSC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

(KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Karuna Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.97%), Price T Rowe Associates Inc. MD (6.63%), BlackRock Inc. (6.60%), Wellington Management Group LLP (4.29%), State Street Corp (2.66%) and Geode Capital Management LLC (1.61%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends.

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KRTX stock can currently be purchased for approximately $236.30.

Karuna Therapeutics (NASDAQ:KRTX) has a market capitalization of $8.85 billion and generates $10.64 million in revenue each year. The company earns $-276,340,000.00 in net income (profit) each year or ($9.57) on an earnings per share basis.

The company employs 118 workers across the globe.

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The official website for the company is karunatx.com. The company can be reached via phone at (857) 449-2244 or via email at investors@karunatx.com.